Clinical Research
Using Novel Technology for Developing New Ways to Deliver and Experience New Medicines
Overview
Our Pharmaceutical Medicines
CURE is conducting clinical research on a variety of active pharmaceutical ingredients (APIs), both internally and through partnerships, mostly utilizing our proprietary drug delivery platform CUREfilm®. The focus of our programs is addressing novel approaches to meaningful disease states that are either undercovered or underappreciated by larger pharmaceutical players. These areas have high barriers to entry and benefit from drug delivery expertise. Our strategy is to capture these opportunities wherever possible using the 505(b)2 regulatory pathway, which enables us to seek regulatory approval at a faster pace than other pathways.
STRATEGIC
Approach
- PRODUCT DEVELOPMENT/DRUG DELIVERY EXPERTISE
- PROPRIETARY PLATFORM TECHNOLOGY
- STRATEGIC FOCUS ON LIKELIHOOD OF SUCCESS
- ABBREVIATED REGULATORY PATHWAY – 505(b)2
- DIFFERENTIATED DOSAGE FORMS/ROUTE OF ADMIN.
- MARKET/COMMERCIALIZATION
CURE PHARMACEUTICAL
Clinical Pipeline
Formulation Development
Clinical Development
Regulatory Filing
Launch
- CUREfilm® Blue (Sildenafil Citrate) 77%
- CUREfilm® Anti-Viral 52%
- CUREfilm® Mental Health Disorders (Multiple Compounds) 42%
- CUREfilm® Central Nervous System Disorders 42%
FOR LICENSING OPPORTUNITIES AND INDUSTRY PARTNERSHIPS
Call 805.824.0410 or email us below:
PHARMACEUTICAL
Focus Areas
Focus Area
Novel Delivery of Known APIs
Focus Area
Unmet Need Applications
Focus Area
Scheduled Compounds
With licensed manufacturing capabilities, and drug delivery expertise, CURE is uniquely positioned as a mid-scale pharmaceutical company, and well positioned to explore the application of FDA compounds of interest for a variety of indications in high-need areas.
CUREfilm® products
Optimized Delivery
Active ingredients in the CUREfilm® dose form can be either pre-solubilized within its matrix or encapsulated, or both for more effective absorption and/or sustained release. As oral thin films quickly dissolve, no water is required for their administration, improving patient compliance – especially among the elderly, children, and in conditions where patients have difficulty in swallowing.
Novel Delivery of APIs
Specific release profiles
Increased bioavailability
Better patient experience
Protection from degradation
enhancing stability and extending shelf life.